ProtoKinetix Announces Independent Group of Validation Trials by European Hospital Georges Pompidou

ProtoKinetix Incorporated (OTCBB: PKTX) - We are pleased to announce that ProtoKinetix (OTCBB:PKTX) has arranged (through *Dr. Jean-Marie Dupuy) an extensive independent group of validation trials on the RECAF ™ receptor site by European Hospital Georges Pompidou of Paris, France.
Upon completion, these trials will confirm the existence of a receptor site, unique to cancer cells, that binds the molecule alpha fetaprotein.

RECAF ™ (Receptor Alpha Fetaprotein) is a carbohydrate molecule that is located on the surface of cancer cells. RECAF ™ makes it possible to specifically target and treat cancer with antibodies to stop cancer growth without damaging healthy cells. RECAF ™ technology is patented and owned by BioCurex, Inc. (BOCX:OTCBB). In order to develop a therapeutic product that targets only malignant cells, ProtoKinetix will develop antibodies that will be:

*Dr. Jean-Marie Dupuis is a world recognized medical scientist, formerly Medical Director of Pasteur Merieux Connaught.
ProtoKinetix Inc.
ProtoKinetix Inc. is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies.  The company has focused on the new generation of monoclonal antibodies termed “super-antibodies”.  We have been licensed to use super-antibody technology to produce antibodies expressed against the RECAF ™ receptor site on the cell surface of many malignancies. ProtoKinetix will use this technology to create therapeutic antibodies to help in the treatment of cancers.  ProtoKinetix is positioned to leverage existing products and intellectual properties through a series of collaborative relationships into effective therapeutic agents.

Company Office:                                      
1500 – 885 West Georgia St. 
Vancouver, BC  V6C 3E8   

Investor Contact:
Aurelius Consulting Group, Inc.
(407) 644-4256
aurelius@cfl.rr.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward -looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.